
Exelixis (EXEL) Stock Forecast & Price Target
Exelixis (EXEL) Analyst Ratings
Bulls say
Exelixis is a promising biopharmaceutical firm with a strong focus on cancer treatments. The company's current portfolio includes successful products like Cometriq and Cabometyx, with more potential treatments in the pipeline. Despite the potential risks, including generic erosion and upcoming patent expirations, the company's cash generation and share repurchase program make it an attractive investment opportunity for those seeking long-term growth. The recent positive trend in OS benefit for the zanza+ICI regimen in all 3L CRC patients further solidifies our positive outlook for the company.
Bears say
Exelixis is facing a potential setback for its product, Cabometyx, as the dual primary endpoint of overall survival (OS) in the non-liver metastases (NLM) subgroup of the STELLAR-303 pivotal trial evaluating Zanzalintinib in combination with atezolizumab did not reach statistically significant results. However, the company's diversified pipeline and upcoming FDA approval decision on December 6th for Zanzalintinib and Tecentriq in 2+ MSI-high CRC could still yield potential growth opportunities. Key risks for the company include potential setbacks in product development, competitive and partnership risks, and macroeconomic and geopolitical uncertainties.
This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.
Exelixis (EXEL) Analyst Forecast & Price Prediction
Start investing in Exelixis (EXEL)
Order type
Buy in
Order amount
Est. shares
0 shares